Today's Date: July 28, 2021
Discover the History of Pisco, the Spirit Drink That Was Born in Peru 400 Years Ago   •   LK Bennett Launches Rental   •   Stanley Black & Decker Named to Forbes Best Employers for Women 2021   •   Pitney Bowes Named One of Forbes’ Best Employers for Women 2021   •   Athleta Launches AthletaWell, an Immersive Digital Platform for Women to Connect on a Range of Topics Rooted in Female Wellbeing   •   Professional Tri-Athlete Lorcan Redmond Uses Signia Active to Optimize Performance in All Situations   •   AARP Awards $3.2 Million for 244 Community Projects   •   U.S. Women's National Team Players Association Receives Record $1 Million Contribution in Fight for Equal Pay from Women's Appar   •   Cayman Kelly Appears in Promo for New Season of 'The Incredible Dr. Pol' - Fans Can Catch the National Voice of ESPN and NFL Mon   •   Merrill Studies Reveal Challenges Diverse Communities Overcome to Achieve Success and Grow their Wealth   •   Knorr® and Boys & Girls Clubs of America Join Forces to Make Nutritious Food Accessible to Families Across the Country   •   New European Published Study Shows LuViva Detects 20% More Precancerous and Cancerous Cervical Disease than HPV Test   •   Mycovia Pharmaceuticals Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Oteseconazole for the Trea   •   PlayStation 5 Surpasses 10 Million Units Sold, Remains the Fastest Selling Console in Sony Interactive Entertainment History   •   BuzzBallz Chili Mango Is Here, and the Name Says It All!   •   Europe's Top 5 Affordable Retirement Havens in 2021--InternationalLiving.com   •   Coca-Cola to Auction Its First-Ever NFT Collectibles on International Friendship Day   •   Wharton Surpasses Historic Milestone of 50% Women in MBA Class of 2023   •   HelloFresh Market Launches in U.S., Expanding Beyond Weeknight Dinners to Everyday Essentials   •   New Research Reveals Price No Longer Primary Driver of Travel Decisions
Bookmark and Share

Gynesonics Announces Positive Payer Coverage Issued by Blue Cross Blue Shield of Florida (Florida Blue) for the Sonata Treatment

REDWOOD CITY, Calif. , June 10 /Businesswire/ - Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today Blue Cross Blue Shield of Florida (Florida Blue) has released a coverage policy for its Sonata® Procedure.1 The addition of the Florida Blue policy allows another 5 million covered lives in Florida to have access to this minimally invasive procedure.2 The Sonata technology platform integrates the first and only commercial intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, providing an incision-free, uterus-preserving, transcervical treatment for symptomatic uterine fibroids. The Sonata Treatment is a breakthrough alternative to hysterectomy and myomectomy, and can treat a wide range of fibroid types, sizes, and locations. Fibroids are treated from inside the uterus, so the Sonata Treatment requires no incisions, no tissue is surgically removed, and the uterus is preserved.

“This is a great decision by Florida Blue that recognizes the importance of offering this minimally invasive option to women. There are a large number of women in my practice that are looking for a procedure that can be done without incisions and with a rapid recovery. Many women suffer the symptoms of uterine fibroids rather than have invasive surgery and I look forward to offering my patients the Sonata Procedure,” said David Adler, DO, FACOG. “I have seen the evolution of minimally invasive fibroid treatment options and Sonata is the procedure that will allow us to treat symptomatic uterine fibroids in the least costly and most patient friendly setting. The Sonata Procedure also provides exceptional savings to the overall healthcare system.”

In the SONATA clinical trial, within three months following their Sonata Treatment, 86 percent of women experienced a reduction in heavy menstrual bleeding and 95 percent of patients experienced a reduction in menstrual bleeding by 12 months. Additionally, 50 percent of women return to normal activities the next day. The overall impact of treatment with Sonata was significant for these women, with 97 percent of women at 12 months indicating they would recommend the procedure. Women were followed in the study long-term which demonstrated durable symptom relief for three years.3

“The announcement of this coverage policy from Florida Blue is exciting and demonstrates the value they place in providing the best possible care for women in Florida. This greatly expands the options available to women suffering with symptomatic uterine fibroids and does so in a way that avoids the cost of traditional surgical treatment,” said Chris Owens, President and CEO of Gynesonics. “Florida Blue and other leading health insurance companies are listening to patients and providers. They are recognizing the clinical efficacy of the Sonata Procedure and as a result are creating access to a less invasive treatment option with the Sonata System.”

For more information about the Sonata System, please visit https://gynesonics.com/us/sonata-system/.

References

  1. http://mcgs.bcbsfl.com/MCG?mcgId=02-56000-30&pv=false
  2. https://www.floridablue.com/about-us/newsroom
  3. https://gynesonics.com/us/publications/

About Sonata System

The Sonata System uses radiofrequency energy to ablate fibroids under real time sonography guidance from within the uterine cavity, utilizing the first and only intrauterine ultrasound transducer. The system includes a proprietary graphical user interface (SMART Guide), enabling the operator to target fibroids and optimize treatment. The Sonata System provides incision-free transcervical access for a uterus-preserving fibroid treatment. This intrauterine approach is designed to avoid the peritoneal cavity. Most side effects are typically minor and temporary. The Sonata System is CE marked and is approved for sale in the European Union, the United Kingdom and the United States.

About Gynesonics

Gynesonics is a women’s healthcare company focused on advancing women’s health, by developing minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications. Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids. Gynesonics headquarters is in Redwood City, CA. For more information, go to www.gynesonics.com.


STORY TAGS: Insurance, Surgery, Medical Devices, Women, Professional Services, Radiology, Health, Consumer, General Health, California, Florida, Product/Service, United States, North America,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News